Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

25.37 +0.14 (+0.55%)
Official Closing Price Updated: 4:10 PM EST, Dec 12, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 38,608,721
Open 25.18
Bid (Size) 25.34 (5)
Ask (Size) 25.35 (33)
Prev. Close 25.23
Today's Range 25.06 - 25.48
52wk Range 24.48 - 31.54
Shares Outstanding 5,606,688,356
Dividend Yield 6.62%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Pfizer Declares First-Quarter 2025 Dividend
From Pfizer Inc
Via Business Wire
Gilead Unveils New Yearly HIV Injection To Offer Hope for Less Frequent Preventive Dosing
Gilead's once-yearly injectable lenacapavir shows promising results in HIV prevention, with a 96% reduction in infections and plans for regulatory filings by 2027. 
Via Benzinga

Performance

YTD
-14.67%
-14.67%
1 Month
-3.32%
-3.32%
3 Month
-14.46%
-14.46%
6 Month
-8.28%
-8.28%
1 Year
-11.23%
-11.23%

More News

Read More
Pfizer's Cancer Drug Ibrance Combo Therapy Extends Median Progression-Free Survival By Over 15 Months In certain Of Breast Cancer Patients
Via Benzinga
Pfizer’s IBRANCE® in Combination with Standard-of-Care Therapies Extends Median Progression-Free Survival by Over 15 Months in Phase 3 PATINA Study in Patients with HR+, HER2+ Metastatic Breast Cancer
From Pfizer Inc.
Via Business Wire
Pfizer's Options: A Look at What the Big Money is Thinking
Via Benzinga
Cracking The Code: Understanding Analyst Reviews For Pfizer
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Arvinas-Pfizer Partner Cancer Drug Trial Shows 63% Clinical Benefit In Breast Cancer Patients
Via Benzinga
Pfizer Invites Public to View and Listen to Webcast of December 17 Conference Call with Analysts to Provide Full-Year 2025 Financial Guidance
From Pfizer Inc.
Via Business Wire
Arvinas and Pfizer Announce Initial Phase 1b Data from the TACTIVE-U Sub-Study of Vepdegestrant in Combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium
From Arvinas Inc.
Via GlobeNewswire
3 Magnificent S&P 500 Dividend Stock Down 35% to Buy and Hold Forever
Via The Motley Fool
Topics Stocks
Exposures US Equities
Should You Buy the S&P 500's Highest-Yielding Dividend Stocks Heading Into 2025?
Via The Motley Fool
Topics Stocks
Exposures US Equities
Want an Extra $1,000 of Dividend Income in 2025? Invest $11,400 in These 3 High-Yield Stocks.
Via The Motley Fool
Pfizer Showcases Scientific Leadership in Breast Cancer and Blood Disorders Across More than 100 Presentations at ASH and SABCS
From Pfizer Inc.
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Should You Forget Pfizer and Buy These Unstoppable Stocks Instead?
Via The Motley Fool
This Healthcare Stock Is a Favorite of Billionaires. But Is It a Buy?
Via The Motley Fool
Got $5,000? These 3 Growth Stocks Are Bargain Buys Right Now.
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Pfizer's New Chief Scientific Officer Charts R&D Vision For High And Low-Risk Investments
Via Benzinga
Valneva's Chikungunya Shot Shows Strong, Long-Lasting Antibody Persistence At Three Years, Comparable In Older And Younger Adults
Via Benzinga
Weight Loss Drug Wars Heat Up: Amgen Challenges Eli Lilly, Novo's Dominance
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
3 Magnificent Dividend Stocks With Yields Above 6% to Buy in December
Via The Motley Fool
Should You Buy More Shares Of Your Loser Stocks?
Via Talk Markets
Topics Stocks / Equities
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.